Business
Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a
About this update from Replimune Group, Inc.
[{"type":"text","content":"Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression in responding patients since the data snapshot presented in December 2022 Overall response rate (ORR) of 37.4%, with clinically meaningful activity across the range of anti-PD1 failed cutaneous melanoma settings enrolled, including in patients with moderate-high tumor burden and visceral disease RP2 demonstrated an acceptable benefit risk profile and meaningful antitumor activity in patients with uveal melanoma from the ongoing RP2 Phase 1 trial WOBURN, Mass., June 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced updated data from the first 75 patients in the anti-PD1 failed melanoma cohort of the IGNYTE clinical trial along with data from the ongoing Phase 1 trial of RP2 combined with nivolumab in patients with uveal melanoma are being presented at the ASCO annual meeting. The anti-PD1 failed melanoma cohort of the IGNYTE clinical trial evaluating RP1 (vusolimogene oderparepvec) in combination with nivolumab is registration-directed. “We are excited to share further data from these ongoing clinical trials evaluating our novel tumor-directed oncolytic immunotherapies, RP1 and RP2,” said Robert Coffin, President and Chief Research & Development Officer of Replimune. “The IGNYTE data demonstrate RP1 combined with nivolumab provides deep and durable responses with clinically meaningful rates of response in each of the anti-PD1 failed settings enrolled, and further highlights the potent systemic activity in tumors which have not been injected with RP1. These data indicate that RP1 has the potential to become a valuable new treatment option for melanoma patients following progression on anti-PD1 therapy, where treatment options are currently limited. Additionally, the data from RP2 in combination with nivolumab in uveal melanoma demonstrates a promising signal in a challenging tumor type that predominantly metastasizes to the liver, which could unlock additional opportunities for our oncolytic immunotherapies.” Updated Data from the IGNYTE Clinical Trial Cohort Evaluating RP...